Latest from Wistar Institute

In a multi-institutional collaborative study, scientists at The Wistar Institute and the Medical University of Vienna, Austria, have identified the role of tumor-infiltrating or tumor-associated B-cells (
Prestigious National Cancer Institute (NCI) grant awarded for nearly $8 million to pursue unencumbered research on cancer progression.
Scientists from The Wistar Institute demonstrate how a mutation in ovarian clear cell carcinoma can be exploited to design a targeted treatment.
The Wistar Institute, an international biomedical research leader in cancer, immunology, infectious diseases, and vaccines, announces the appointment of Joseph M. Salvino, PhD, as professor in the Molecular and Cellular Oncogenesis Program and Scientific Director of the Institutes Molecular Screening Facility.
The Wistar Institute, an international biomedical research leader in cancer, immunology and infectious diseases, welcomes Kenneth W. Hance, Ph.D., M.P.H., Director of Antibody Therapies, Immuno-Oncology & Combinations DPU at GlaxoSmithKline (GSK), as its first Visiting Professor from GSK at Wistar.
The total funding includes a National Cancer Institute award for more than $6 million that supports multidisciplinary prostate cancer research with goal of developing future drug therapies.
The Wistar Institute, an international leader in cancer, immunology and infectious diseases research, is pleased to announce that Ashani Weeraratna, PhD, associate professor and program leader in the Tumor Microenvironment and Metastasis Program, has been named the Ira Brind Associate Professor.
Amid growing evidence of their importance in the immune system, myeloid-derived suppressor cells are gaining traction as a target for anticancer therapies.
Publication Bottom Border
Border Publication